Browse by UCL people
Group by: Type | Date
Jump to: Article | Conference item
Number of items: 52.
Article
Abdel-Gadir, A;
Berber, R;
Porter, JB;
Quinn, PD;
Suri, D;
Kellman, P;
Hart, AJ;
... Skinner, JA; + view all
(2016)
Detection of metallic cobalt and chromium liver deposition following failed hip replacement using T2* and R2 magnetic resonance.
Journal of Cardiovascular Magnetic Resonance
, 18
, Article 29. 10.1186/s12968-016-0248-z.
|
 |
|
Abdel-Gadir, A;
Vorasettakarnkij, Y;
Ngamkasem, H;
Nordin, S;
Ako, EA;
Tumkosit, M;
Sucharitchan, P;
... Moon, JC; + view all
(2016)
Ultrafast Magnetic Resonance Imaging for Iron Quantification in Thalassemia Participants in the Developing World The TIC-TOC Study (Thailand and UK International Collaboration in Thalassaemia Optimising Ultrafast CMR).
Circulation
, 134
(5)
pp. 432-434.
10.1161/CIRCULATIONAHA.116.022803.
|
|
|
Aneke, JC;
Huntley, N;
Porter, J;
Eleftheriou, P;
(2016)
Effect of automated red cell exchanges on oxygen saturation on-air, blood parameters and length of hospitalization in sickle cell disease patients with acute chest syndrome.
Nigerian Medical Journal
, 57
(3)
pp. 190-193.
10.4103/0300-1652.184073.
|
|
|
Cappellini, MD;
Taher, AT;
Piga, A;
Shah, F;
Voskaridou, E;
Viprakasit, V;
Porter, JB;
... Oliva, EN; + view all
(2023)
Health-related quality of life in patients with β-thalassemia: Data from the phase 3 BELIEVE trial of luspatercept.
European Journal of Haematology
, 111
(1)
pp. 113-124.
10.1111/ejh.13975.
|
|
Cappellini, MD;
Porter, J;
Origa, R;
Forni, GL;
Voskaridou, E;
Galacteros, F;
Taher, AT;
... Hermine, O; + view all
(2019)
Sotatercept, a novel transforming growth factor beta ligand trap, improves anemia in beta-thalassemia: a phase II, open-label, dose-finding study.
Haematologica
, 104
(3)
pp. 477-484.
10.3324/haematol.2018.198887.
|
|
|
Cappellini, MD;
Porter, JB;
Viprakasit, V;
Taher, AT;
(2018)
A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies?
Blood Reviews
, 32
(4)
pp. 300-311.
10.1016/j.blre.2018.02.001.
|
|
|
Cappellini, MD;
Viprakasit, V;
Taher, AT;
Georgiev, P;
Kuo, KHM;
Coates, T;
Voskaridou, E;
... BELIEVE Investigators; + view all
(2020)
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia.
The New England Journal of Medicine
, 382
(13)
pp. 1219-1231.
10.1056/NEJMoa1910182.
|
|
Carpenter, JP;
Alpendurada, F;
Deac, M;
Maceira, A;
Garbowski, M;
Kirk, P;
Walker, JM;
... Pennell, DJ; + view all
(2010)
Right ventricular volumes and function in thalassemia major patients in the absence of myocardial iron overload.
Journal of Cardiovascular Magnetic Resonance
, 12
, Article 24. 10.1186/1532-429X-12-24.
|
 |
|
Chan, E;
Sammaraiee, Y;
Banerjee, G;
Martin, AF;
Farmer, S;
Cowley, P;
Sayal, P;
... Werring, DJ; + view all
(2021)
Neuropsychological and neuroimaging characteristics of classical superficial siderosis.
Journal of Neurology
, 268
pp. 4238-4247.
10.1007/s00415-021-10548-z.
|
|
Davis, BA;
Allard, S;
Qureshi, A;
Porter, JB;
Pancham, S;
Win, N;
Cho, G;
... British Society for Haematology, .; + view all
(2017)
Guidelines on red cell transfusion in sickle cell disease Part II: indications for transfusion.
British Journal of Haematology
, 176
(2)
pp. 192-209.
10.1111/bjh.14383.
|
|
|
Farmakis, Dimitrios;
Porter, John;
Taher, Ali;
Cappellini, Maria Domenica;
Angastiniotis, Michael;
Eleftheriou, Androulla;
(2022)
2021 Thalassaemia International Federation Guidelines for the Management of Transfusion-dependent Thalassemia.
HemaSphere
, 6
(8)
, Article e732. 10.1097/HS9.0000000000000732.
|
|
Garbowski, Maciej W;
Cabantchik, Ioav;
Hershko, Chaim;
Hider, Robert;
Porter, John B;
(2023)
The clinical relevance of detectable plasma iron species in iron overload states and subsequent to intravenous iron-carbohydrate administration.
American Journal of Hematology
, 98
(3)
pp. 533-540.
10.1002/ajh.26819.
|
|
Garbowski, Maciej W;
Porter, John B;
Hider, Robert;
(2021)
Response to Cabantchik and Hershko commentary "Plasma nontransferrin bound iron-nontransferrin bound iron revisited: Implications for systemic iron overload and in iv iron supplementation".
American Journal of Hematology
, 97
(2)
E58-E59.
10.1002/ajh.26419.
|
|
Garbowski, MW;
Ugidos, M;
Risueño, A;
Shetty, JK;
Schwickart, M;
Hermine, O;
Porter, JB;
... Vodala, S; + view all
(2023)
Luspatercept stimulates erythropoiesis, increases iron utilization, and redistributes body iron in transfusion-dependent thalassemia.
American Journal of Hematology
10.1002/ajh.27102.
(In press).
|
|
|
Garbowski, MW;
Bansal, S;
Porter, JB;
Mori, C;
Burckhardt, S;
Hider, RC;
(2020)
Intravenous iron preparations transiently generate non-transferrin-bound iron from two proposed pathways.
Haematologica
10.3324/haematol.2020.250803.
(In press).
|
|
Garbowski, MW;
Carpenter, JP;
Smith, G;
Roughton, M;
Alam, MH;
He, T;
Pennell, DJ;
(2014)
Biopsy-based calibration of T2* magnetic resonance for estimation of liver iron concentration and comparison with R2 Ferriscan.
Journal of Cardiovascular Magnetic Resonance
, 16
(40)
10.1186/1532-429X-16-40.
|
|
|
Garbowski, MW;
Evans, P;
Vlachodimitropoulou, E;
Hider, R;
Porter, JB;
(2017)
Residual erythropoiesis protects against myocardial hemosiderosis in transfusion-dependent thalassemia by lowering labile plasma iron via transient generation of apotransferrin.
Haematologica
, 102
pp. 1640-1649.
10.3324/haematol.2017.170605.
|
|
|
Garbowski, MW;
Ma, Y;
Fucharoen, S;
Srichairatanakool, S;
Hider, R;
Porter, JB;
(2016)
Clinical and methodological factors affecting non-transferrin-bound iron values using a novel fluorescent bead assay.
Translational Research
, 177
19-30.e5.
10.1016/j.trsl.2016.05.005.
|
|
|
Howard, J;
Hemmaway, CJ;
Telfer, P;
Layton, DM;
Porter, J;
Awogbade, M;
Mant, T;
... Lehrer-Graiwer, J; + view all
(2019)
A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease.
Blood
, 133
(17)
pp. 1865-1875.
10.1182/blood-2018-08-868893.
|
|
Hutachok, N;
Angkasith, P;
Chumpun, C;
Fucharoen, S;
Mackie, IJ;
Porter, JB;
Srichairatanakool, S;
(2020)
Anti-Platelet Aggregation and Anti-Cyclooxygenase Activities for a Range of Coffee Extracts (Coffea arabica).
Molecules
, 26
, Article 10. 10.3390/molecules26010010.
|
|
|
Jackson, LH;
Vlachodimitropoulou, E;
Shangaris, P;
Roberts, TA;
Ryan, TM;
Campbell-Washburn, AE;
David, AL;
... Stuckey, DJ; + view all
(2017)
Non-invasive MRI biomarkers for the early assessment of iron overload in a humanized mouse model of β-thalassemia.
Scientific Reports
, 7
, Article 43439. 10.1038/srep43439.
|
|
|
Kantaris, X;
Shevlin, M;
Porter, J;
Myers, L;
(2020)
Development of the Thalassaemia Adult Life Index (ThALI).
Health and Quality of Life Outcomes
, 18
, Article 180. 10.1186/s12955-020-01437-6.
|
|
|
Kirk, P;
Sheppard, M;
Carpenter, J-P;
Anderson, L;
He, T;
St Pierre, T;
Galanello, R;
... Pennell, DJ; + view all
(2017)
Post-mortem study of the association between cardiac iron and fibrosis in transfusion dependent anaemia.
Journal of Cardiovascular Magnetic Resonance
, 19
(1)
, Article 36. 10.1186/s12968-017-0349-3.
|
|
|
Koonyosying, P;
Uthaipibull, C;
Fucharoen, S;
Koumoutsea, EV;
Porter, JB;
Srichairatanakool, S;
(2019)
Decrement in Cellular Iron and Reactive Oxygen Species, and Improvement of Insulin Secretion in a Pancreatic Cell Line Using Green Tea Extract.
Pancreas
, 48
(5)
pp. 636-643.
10.1097/MPA.0000000000001320.
|
|
|
Koumoutsea, EV;
Garbowski, M;
Porter, J;
(2015)
Synergistic intracellular iron chelation combinations: mechanisms and conditions for optimizing iron mobilization.
British Journal of Haematology
, 170
(6)
pp. 874-883.
10.1111/bjh.13512.
|
|
|
Liu, ZJ;
Deschmann, E;
Ramsey, HE;
Feldman, HA;
Psaila, B;
Cooper, N;
Vlachodimitropoulou, E;
... Sola-Visner, M; + view all
(2022)
Iron status influences the response of cord blood megakaryocyte progenitors to eltrombopag in vitro.
Blood Advances
, 6
(1)
pp. 13-27.
10.1182/bloodadvances.2021004207.
|
|
|
Musallam, KM;
Taher, AT;
Cappellini, MD;
Hermine, O;
Kuo, KHM;
Sheth, S;
Viprakasit, V;
(2022)
Untreated Anemia in Nontransfusion-dependent β-thalassemia: Time to Sound the Alarm.
HemaSphere
, 6
(12)
, Article e806. 10.1097/HS9.0000000000000806.
|
|
Paradee, N;
Utama-Ang, N;
Uthaipibull, C;
Porter, JB;
Garbowski, MW;
Srichairatanakool, S;
(2020)
Extracts of Thai Perilla frutescens nutlets attenuate tumour necrosis factor-α-activated generation of microparticles, ICAM-1 and IL-6 in human endothelial cells.
Bioscience Reports
, 40
(5)
, Article BSR20192110. 10.1042/BSR20192110.
|
|
|
Pennell, DJ;
Porter, JB;
Cappellini, MD;
Chan, LL;
El-Beshlawy, A;
Aydinok, Y;
Ibrahim, H;
... Taher, A; + view all
(2011)
Continued improvement in myocardial T2(star) over two years of deferasirox therapy in beta-thalassemia major patients with cardiac iron overload.
Haematologica - The Hematology Journal
, 96
(1)
48 - 54.
10.3324/haematol.2010.031468.
|
|
|
Porter, J;
Taher, A;
Viprakasit, V;
Kattamis, A;
Coates, TD;
Garbowski, M;
Durrenberger, F;
... Cappellini, MD; + view all
(2021)
Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in β-thalassemia: current evidence and future clinical development.
Expert Review of Hematology
, 14
(7)
pp. 633-644.
10.1080/17474086.2021.1935854.
|
|
|
Porter, JB;
Scrimgeour, A;
Martinez, A;
James, L;
Aleku, M;
Wilson, R;
Muckenthaler, M;
... Campion, GV; + view all
(2023)
SLN124, a GalNAc conjugated 19-mer siRNA targeting tmprss6, reduces plasma iron and increases hepcidin levels of healthy volunteers.
American Journal of Hematology
, 98
(9)
pp. 1425-1435.
10.1002/ajh.27015.
|
|
Porter, JB;
(2020)
Iron Through the Prism of Haematology.
British Journal of Haematology
, 191
(4)
pp. 587-592.
10.1111/bjh.17164.
|
|
|
Porter, JB;
Cappellini, MD;
Kattamis, A;
Viprakasit, V;
Musallam, KM;
Zhu, Z;
Taher, AT;
(2017)
Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions.
British Journal of Haematology
, 176
(2)
pp. 288-299.
10.1111/bjh.14373.
|
|
|
Porter, JB;
Elalfy, M;
Taher, A;
Aydinok, Y;
Lee, SH;
Sutcharitchan, P;
El-Ali, A;
... El-Beshlawy, A; + view all
(2017)
Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia.
European Journal of Haematology
, 98
(3)
pp. 280-288.
10.1111/ejh.12830.
|
|
|
Porter, JB;
Garbowski, M;
(2014)
The Pathophysiology of Transfusional Iron Overload.
Hematology/Oncology Clinics of North America
, 28
(4)
pp. 683-701.
10.1016/j.hoc.2014.04.003.
|
|
|
Porter, JB;
Garbowski, MW;
(2018)
Interaction of Transfusion and Iron Chelation in Thalassemias.
Hematology/Oncology Clinics of North America
, 32
(2)
pp. 247-259.
10.1016/j.hoc.2017.11.010.
|
|
Porter, JB;
Walter, PB;
Neumayr, LD;
Evans, P;
Bansal, S;
Garbowski, M;
Weyhmiller, MG;
... Vichinsky, E; + view all
(2014)
Mechanisms of plasma non-transferrin bound iron generation: insights from comparing transfused diamond blackfan anaemia with sickle cell and thalassaemia patients.
British Journal of Haematology
, 167
(5)
pp. 692-696.
10.1111/bjh.13081.
|
|
Porter, JB;
Wood, J;
Olivieri, N;
Vichinsky, EP;
Taher, A;
Neufeld, E;
Giardina, P;
... Trachtenberg, F; + view all
(2013)
Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone.
Journal of Cardiovascular Magnetic Resonance
, 15
, Article 38. 10.1186/1532-429X-15-38.
|
|
|
Prommaban, A;
Utama-Ang, N;
Chaikitwattana, A;
Uthaipibull, C;
Porter, JB;
Srichairatanakool, S;
(2020)
Phytosterol, Lipid and Phenolic Composition, and Biological Activities of Guava Seed Oil.
Molecules
, 25
(11)
, Article 2474. 10.3390/molecules25112474.
|
|
|
Sado, D;
White, SK;
Piechnik, SK;
Banypersad, SM;
Treibel, TA;
Fontana, M;
Captur, G;
... Moon, J; + view all
(2013)
Native T1 lowering in iron overload and Anderson Fabry disease; a novel and early marker of disease.
Journal of Cardiovascular Magnetic Resonance
, 15
(Suppl 1)
, Article O71. 10.1186/1532-429X-15-S1-O71.
|
|
|
Sammaraiee, Y;
Banerjee, G;
Farmer, S;
Hylton, B;
Cowley, P;
Eleftheriou, P;
Porter, J;
(2019)
Risks associated with oral deferiprone in the treatment of infratentorial superficial siderosis.
Journal of Neurology
, 267
, Article 682. 10.1007/s00415-019-09577-6.
|
|
Settakorn, K;
Kongkarnka, S;
Chompupoung, A;
Svasti, S;
Fucharoen, S;
Porter, JB;
Srichairatanakool, S;
(2022)
Effects of green tea extract treatment on erythropoiesis and iron parameters in iron-overloaded β-thalassemic mice.
Frontiers in Physiology
, 13
, Article 1053060. 10.3389/fphys.2022.1053060.
|
|
Siddharthan, T;
Grigsby, M;
Miele, CH;
Bernabe-Ortiz, A;
Miranda, JJ;
Gilman, RH;
Wise, RA;
... Checkley, W; + view all
(2017)
Prevalence and risk factors of restrictive spirometry in a cohort of Peruvian adults.
The International Journal of Tuberculosis and Lung Disease
, 21
(9)
pp. 1062-1068.
10.5588/ijtld.17.0101.
|
|
Taher, AT;
Origa, R;
Perrotta, S;
Kourakli, A;
Ruffo, GB;
Kattamis, A;
Goh, AS;
... Porter, JB; + view all
(2017)
New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study.
American Journal of Hematology
, 92
(5)
pp. 420-428.
10.1002/ajh.24668.
|
|
|
Taher, AT;
Origa, R;
Perrotta, S;
Kouraklis, A;
Belhoul, K;
Huang, V;
Han, J;
... Porter, JB; + view all
(2019)
Influence of patient-reported outcomes on the treatment effect of deferasirox film-coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis.
[Letter].
American Journal of Hematology
, 94
(4)
E96-E99.
10.1002/ajh.25408.
|
|
Taher, AT;
Origa, R;
Perrotta, S;
Kouraklis, A;
Ruffo, GB;
Kattamis, A;
Goh, A-S;
... Porter, JB; + view all
(2018)
Patient-reported outcomes from a randomized phase II study of the deferasirox film-coated tablet in patients with transfusion-dependent anemias.
Health and Quality of Life Outcomes
, 16
, Article 216. 10.1186/s12955-018-1041-5.
|
|
|
Taher, AT;
Porter, JB;
Kattamis, A;
Viprakasit, V;
Cappellini, MD;
(2016)
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes.
Drug Design, Development and Therapy
, 10
pp. 4073-4078.
10.2147/DDDT.S117080.
|
|
|
Taher, AT;
Weber, S;
Han, J;
Bruederle, A;
Porter, JB;
(2019)
Predicting serum ferritin levels in patients with iron overload treated with the film-coated tablet of deferasirox during the ECLIPSE study.
American Journal of Hematology
, 94
(1)
E15-E17.
10.1002/ajh.25322.
|
|
|
Telfer, P;
De la Fuente, J;
Sohal, M;
Brown, R;
Eleftheriou, P;
Roy, N;
Piel, FB;
... Layton, DM; + view all
(2020)
Real-time national survey of COVID-19 in hemoglobinopathy and rare inherited anemia patients.
Haematologica
, 105
(11)
pp. 2651-2654.
10.3324/haematol.2020.259440.
|
|
|
Vila Cuenca, M;
Marchi, G;
Barqué, A;
Esteban-Jurado, C;
Marchetto, A;
Giorgetti, A;
Chelban, V;
... Sanchez, M; + view all
(2020)
Genetic and Clinical Heterogeneity in Thirteen New Cases with Aceruloplasminemia. Atypical Anemia as a Clue for an Early Diagnosis.
International Journal of Molecular Sciences
, 21
(7)
, Article 2374. 10.3390/ijms21072374.
|
|
|
Vlachodimitropoulou, E;
Chen, Y-L;
Garbowski, M;
Koonyosying, P;
Psaila, B;
Sola-Visner, M;
Cooper, N;
... Porter, J; + view all
(2017)
Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator.
Blood
, 130
(17)
pp. 1923-1933.
10.1182/blood-2016-10-740241.
|
Conference item
|
Ako, EOI;
Barber, N;
Kowalik, G;
Steeden, JA;
Porter, J;
Walker, J;
Muthurangu, V;
(2016)
MR-Augmented Cardiopulmonary Exercise Testing - a proof of concept in Sickle Cell Disease.
Presented at: Society for Cardiovascular Magnetic Resonance: 19th Annual SCMR Scientific Sessions, Los Angeles, California, USA.
|
|
